Detalles de la búsqueda
1.
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Invest New Drugs
; 31(4): 833-44, 2013 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-23275061
2.
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.
Nat Cancer
; 2(4): 429-443, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34568836
3.
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.
Oncotarget
; 11(17): 1478-1492, 2020 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32391118
4.
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Cancer Discov
; 10(8): 1174-1193, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32404308
5.
Aurora A-Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy.
Mol Cancer Ther
; 18(12): 2207-2219, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31530649
6.
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.
Cancer Discov
; 9(2): 248-263, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373917
7.
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.
Cancer Cell
; 32(6): 761-776.e6, 2017 Dec 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29232554
8.
Structural studies of Salmonella typhimurium ArnB (PmrH) aminotransferase: a 4-amino-4-deoxy-L-arabinose lipopolysaccharide-modifying enzyme.
Structure
; 10(11): 1569-80, 2002 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-12429098
9.
Structural genomics: bridging functional genomics and structure-based drug design.
Curr Opin Drug Discov Devel
; 5(3): 367-81, 2002 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-12058612
10.
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation.
Mol Cancer Ther
; 13(10): 2253-63, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25122067
11.
Unraveling the genomic determinants of response to CDK4/6 inhibitors.
Oncotarget
; 9(96): 36822-36823, 2018 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30627319
12.
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.
Cancer Res
; 70(17): 6880-90, 2010 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20643778
13.
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
Mol Cancer Ther
; 8(12): 3181-90, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19934279
14.
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
J Biol Chem
; 279(53): 55827-32, 2004 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-15507431
15.
Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator.
EMBO J
; 23(2): 282-93, 2004 Jan 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-14685259
Resultados
1 -
15
de 15
1
Próxima >
>>